Ovarian Cancer
News and reporting on ovarian cancer.
FDA Approves Verastem's Avmapki, Fakzynja Combo for KRAS-Mutant Ovarian Cancer Patients
The agency approved the treatment based on data from 57 patients with previously treated KRAS-mutant recurrent low-grade serous ovarian cancer.
The model combines estimates of skeletal muscle with routinely collected clinical data and unstructured notes and predicts the individual likelihood of cachexia.
With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.
The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.
Cero Therapeutics Advancing Autologous Cell Therapy to Phase I Solid Tumor Trials
The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.
Aug 27, 2024